Eli Lilly Reports Positive Late-Stage Results for Eczema Drug Ebglyss
Eli Lilly reported positive late-stage clinical results for its eczema treatment Ebglyss. The results are for a difficult-to-treat form of atopic dermatitis affecting the hands and feet, potentially expanding the drug's commercial opportunity.
Eli Lilly NYSE:LLY reported positive late-stage clinical results for its eczema treatment Ebglyss, with the data potentially broadening the drug’s commercial opportunity into a difficult-to-treat form of atopic dermatitis affecting the hands and feet. The Phase 3 result adds to Lilly’s immunology portfolio and includes the required 3 token.